Neoadjuvant immunotherapy for high-risk eye melanoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This first-in-human phase 1 study evaluates the safety and feasibility of neoadjuvant immunotherapy using nivolumab plus ipilimumab for patients with high-risk, localized uveal melanoma planned for enucleation. The study will assess pathological response in tumor tissue, distant metastasis-free survival, overall survival, and changes in the tumor microenvironment after treatment. Participants will undergo transvitreal biopsy and standard surgical procedures, with monitoring for adverse events and lab abnormalities. Eligibility requires adults up to 80 years, good performance status, Danish literacy, and specific organ function criteria.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 ≤ 80
* The patient is able to read and understand Danish.
* Primary, localized and treatment-naive uveal melanoma planned for enucleation (high risk/T3-T4) and available for transvitreal biopsies. The initial diagnosis of uveal melanoma is based on ophthalmologic and clinical findings.
* ECOG performance status of 0 or 1 (appendix 2)
* The patient meets the following haematological and biochemical criteria at time of screening: a) AST and ALT ≤2,5 X ULN, b) Serum total bilirubin ≤1,5 X ULN or direct bilirubin ≤ ULN for patient with total bilirubin level \> 1,5 ULN, c) Serum creatinine ≤1,5 X ULN, d) ANC (Absolute Neutrophil Count) ≥1,000/mcL, e) Platelets ≥ 75,000 /mcL, f) Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L
* Signed statement of consent after receiving oral and written study information
* Willingness to participate in the planned treatment and follow-up schedule
* For women of childbearing potential (WOCBP) a negative serum pregnancy test at time of screening and the use of highly effective contraception is required. This applies from screening and until 6 months after treatment.

The following is considered highly effective methods of contraception: 1. Combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal or transdermal), 2. Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable) 3. Intrauterine device (IUD) 4. intrauterine hormone-releasing system (IUS) 5. Bilateral tubal occlusion, 6. Vasectomised partner provided that the vasectomy is confirmed successful, 7. Sexual abstinence defined as refraining from heterosexual intercourse. WOCBP must also agree to refrain from egg donation, storage, or banking during these same time periods.

\- Men with female partner of childbearing potential must: 1. Use a condom during sexual intercourse from screening and until 6 months after treatment. 2.

Ensure that their partner uses a highly effective method of contraception (as described above) 3. Agree to refrain from sperm donation, storage, or banking

Exclusion criteria

* A history of prior malignancies. Patients treated for another malignancy can participate if they are without signs of disease for a minimum of 2 years after treatment. Subjects with curatively treated ductal carcinoma in situ (DCIS or LCIS) breast cancer for which they are taking hormonal therapy is acceptable. Resectable squamous or basal cell carcinoma of the skin is acceptable.
* Requirement for immunosuppressive doses of systemic corticosteroids (\>10 mg/day prednisone or equivalent) or other immunosuppressive drugs within the last 3 weeks prior to screening
* The patient has any condition that will interfere with patient compliance or safety (including but not limited to psychiatric or substance abuse disorders)
* The patient is pregnant or breastfeeding
* The patient has an active infection requiring systemic therapy
* Significant medical disorder according to investigator; e.g severe asthma or chronic obstructive lung disease, dysregulated heart disease or dysregulated diabetes mellitus.
* Concurrent treatment with other experimental drugs
* Any significant active autoimmune disease
* Severe allergy or anaphylactic reactions earlier in life
* Known hypersensitivity to one of the active drugs or one or more of the excipients.

Where it's running

• National Center for Cancer Immune Therapy, Department of Oncology, Herlev Hospital
  Herlev, Herlev, Denmark Recruiting

Study contacts

• Study coordinator: Inge Marie Svane, Professor, MD
• Email: inge.marie.svane@regionh.dk
• Phone: 004538683868

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combination treatment for liver metastases from uveal melanoma

  This study is testing a new combination treatment for patients with liver metastases from uveal melanoma to see if adding a special delivery method can help them live longer without their cancer getting worse.

  Recruiting at 3 sites Phase 3 Vastra Gotaland Region · Gothenburg and 5 other locations · NCT06519266

• First-Line Nivolumab plus Ipilimumab in unresectable hepatocellular carcinoma

  This study tests whether the combination of nivolumab and ipilimumab is safe and effective for adults with unresectable liver cancer in real-world care in Japan.

  Recruiting at 2 sites Bristol-Myers Squibb · Minato-ku, Tokyo and 1 other locations · NCT07679061

• 30-minute cycling immediately before nivolumab and ipilimumab for metastatic melanoma

  This trial will test whether a 30-minute cycling session immediately before nivolumab plus ipilimumab boosts immune activity and improves outcomes for people with metastatic melanoma.

  Recruiting Universitätsklinikum Hamburg-Eppendorf · Hamburg, Free and Hanseatic City of Hamburg · NCT07564570

• VSV-IFNβ-NIS plus ipilimumab and nivolumab for advanced or metastatic clear cell renal cell carcinoma

  This trial adds a virus-based therapy (VSV-IFNβ-NIS) to standard immunotherapy (ipilimumab and nivolumab) to see if it helps people with advanced or metastatic clear cell renal cell cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07510334

• Using ctDNA to decide whether to add ipilimumab for people on nivolumab and relatlimab

  This tests whether using a ctDNA blood test to guide adding ipilimumab for adults with advanced or metastatic melanoma on nivolumab and relatlimab leads to longer progression-free survival.

  Recruiting Phase 2 NYU Langone Health · New York, New York · NCT07504796

• Y90 liver radiation plus immunotherapy and targeted drug for unresectable liver cancer

  This test will see if adding Y90 liver radiation to nivolumab, ipilimumab, and lenvatinib helps people with unresectable hepatocellular carcinoma live longer and have better tumor responses.

  Recruiting Phase 1/2 West China Hospital · Chengdu, Sichuan · NCT07482059

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.